Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclosporine
Drug ID BADD_D00551
Description Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_.[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Indications and Usage For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.
Marketing Status Prescription; Discontinued
ATC Code L04AD01; S01XA18
DrugBank ID DB00091
KEGG ID D00184
MeSH ID D016572
PubChem ID 5280754
TTD Drug ID D0O3YF
NDC Product Code 55486-1604; 55486-1602; 11014-0041; 68084-879; 51927-0160; 59573-0001; 0093-9020; 60505-0133; 60505-4630; 52972-0027; 55486-1603; 55361-0025; 0093-5742; 55361-0022; 55361-0023; 0074-5503; 55361-0026; 10702-808; 0074-3108; 11014-0040; 0093-5740; 10888-5040; 47335-506; 0023-9163; 50090-1242; 68084-921; 0078-0241; 0074-3109; 55500-0009; 0078-0110; 0093-5741; 65897-1008; 10888-5041; 0378-8760; 47335-507; 51552-0663; 0078-0274; 68254-2501; 51862-460; 55486-1567; 65086-001; 0074-7269; 51927-0213; 60505-6202; 11014-0033; 60505-4631; 11014-0034; 60505-0134; 68254-0008; 0574-0866; 0172-7313; 66507-0001; 0078-0240; 50090-4476; 0078-0246; 0078-0248; 0093-9019; 63629-8640; 51927-3196; 0093-9018; 47848-004; 72969-017; 0078-0109; 0023-5301; 60505-4632; 51862-458; 52928-005
Synonyms Cyclosporine | Cyclosporine A | Cyclosporin A | Ciclosporin | Cyclosporin | Neoral | Sandimmun Neoral | CyA-NOF | CyA NOF | Sandimmune | Sandimmun | CsA-Neoral | CsA Neoral | CsANeoral | OL 27-400 | OL 27 400 | OL 27400
Chemical Information
Molecular Formula C62H111N11O12
CAS Registry Number 59865-13-3
SMILES CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C (C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C C(C)C)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionT-cell surface glycoprotein CD3 epsilon chainA6H6M1Not Available2246324; 2738100; 8880225; 8288727; 2515162; 6831033; 3871216; 1950737; 2548278; 2846698; 3262683; 7759599; 9869836; 2211719; 3131638; 2809200; 2540100; 9287244; 12082550; 7535569
Bladder perforationvon Willebrand factorP04275T233488249125; 9352228; 9414275; 8589211; 9241755; 7544037; 9351387; 7586318; 2470733; 8615807; 11230807
Bone density decreasedOsteocalcinP02818Not Available8864416; 11303710; 9141540; 11012914; 11446565; 9514219; 9933485
Bone density decreasedParathyroid hormoneP01270T987088864416; 11303710; 9141540; 11012914; 11446565; 9514219; 9933485
ComaGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
Complications of transplanted kidneyvon Willebrand factorP04275T233488249125; 9352228; 9414275; 8589211; 9241755; 7544037; 9351387; 7586318; 2470733; 8615807; 11230807
EncephalopathyGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
Haemolysisvon Willebrand factorP04275T233488249125; 9352228; 9414275; 8589211; 9241755; 7544037; 9351387; 7586318; 2470733; 8615807; 11230807
HypertensionEndothelin-1P05305T2507610930191; 9931093; 8986453
HypertensionNitric oxide synthase, endothelialP29474T0604610930191; 9931093; 8986453
HypertensionNeprilysinP08473T0540910930191; 9931093; 8986453
Nephropathy toxicCalcineurin subunit B type 1P63098Not Available8591053; 7694398; 7592869; 7533090; 7542793; 7524531; 7520696
Renal disorderTransforming growth factor beta-1 proproteinP01137T972579125798; 9987092; 9214404; 12166693; 7564111; 12099512; 12427154
Renal disorderGolgin subfamily A member 2Q08379Not Available9125798; 9987092; 9214404; 12166693; 7564111; 12099512; 12427154
SeizureGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
ThrombosisThrombomodulinP07204T085831848730; 7878634
ThrombosisGuanine nucleotide-binding protein G(q) subunit alphaP50148T122901848730; 7878634
TremorGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.001298%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000948%
Liver function test increased13.03.01.044--Not Available
Acoustic neuroma04.04.04.003; 17.18.02.002; 16.09.02.0020.000519%Not Available
Anal ulcer07.04.01.0010.000519%
Blood immunoglobulin E increased13.06.05.0030.000779%Not Available
Concomitant disease aggravated08.01.03.0630.000745%Not Available
Hyperaldosteronism05.01.01.006; 24.08.04.005; 14.05.04.0060.000519%Not Available
IgA nephropathy20.05.01.016; 10.02.01.0630.000519%Not Available
Lumbar spinal stenosis17.10.03.004; 15.10.04.0080.000779%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000203%Not Available
Mumps11.05.24.001; 07.06.04.0040.000519%Not Available
Normal newborn18.08.06.0010.000519%Not Available
Pulmonary mycosis11.03.05.027; 22.07.08.0130.000519%Not Available
Purulent discharge11.01.08.061; 08.01.03.0760.000519%Not Available
Renal tubular atrophy20.05.03.0220.000519%Not Available
Spinal column stenosis15.10.04.003; 17.10.01.0110.001038%Not Available
Superficial injury of eye12.01.04.032; 06.11.04.0010.002336%Not Available
Threatened labour18.07.01.0090.000519%Not Available
Concomitant disease progression08.01.03.0640.000542%Not Available
Terminal state08.01.03.0790.000519%Not Available
Small intestinal haemorrhage24.07.02.019; 07.12.03.0020.000519%
Candida pneumonia11.03.03.023; 22.07.08.0110.000519%Not Available
Cardiac infection11.01.16.003; 02.01.05.0020.000135%Not Available
Clostridium difficile infection11.02.02.0090.000779%Not Available
Gastrointestinal oedema07.11.01.0120.000519%Not Available
Mitochondrial encephalomyopathy17.13.02.009; 15.05.05.014; 03.18.01.0060.000519%Not Available
General physical condition abnormal13.15.01.0400.000519%Not Available
Neonatal aspiration22.11.01.008; 18.04.09.0070.000519%Not Available
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.000203%Not Available
The 28th Page    First    Pre   28 29    Next   Last    Total 29 Pages